ZL-n-91 PDE4D Inhibitor Selectivity for Lung Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE4 inhibitors for treating lung cancer are limited by their non-specificity, leading to adverse reactions such as gastrointestinal side effects due to their interaction with other PDE family members, and they have a poor prognosis with a 5-year survival rate less than 15% for lung cancer patients.
Innovation Solution
The use of PDE4 inhibitor ZL-n-91, which has a high selectivity for PDE4D, significantly inhibiting lung cancer cell proliferation and metastasis with minimal side effects, offering a targeted approach for drug development against lung cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PDE4 inhibitors (Rolipram, Cilomitast, Roflumilast) are used to treat lung cancer, then they can inhibit tumor growth, but they cause gastrointestinal adverse reactions and other side effects due to poor selectivity
Solution Approach 1:
The patent applies local quality by designing ZL-n-91 with specific molecular characteristics that confer high selectivity for PDE4D subtype. The compound's chemical structure ( featuring a pyrimido[5,4-b]pyridin-4-one core with specific substituents) enables it to selectively inhibit PDE4D while sparing other PDE family members, thereby achieving anti-tumor efficacy without the gastrointestinal side effects associated with non-selective PDE4 inhibitors
Solution Approach 2:
The patent employs parameter changes by optimizing the chemical structure of PDE4 inhibitors to achieve high selectivity for PDE4D. By modifying molecular parameters (substituent groups, stereochemistry, and structural features), ZL-n-91 achieves a selectivity ratio of greater than 100-fold for PDE4D over other PDE isoforms, fundamentally changing the selectivity parameter from the 5-1000 fold range of existing drugs to a highly specific profile that eliminates off-target effects
2Reliability
If high doses of non-selective PDE4 inhibitors are administered to achieve sufficient anti-tumor effect, then tumor inhibition is enhanced, but side effects are exacerbated
Solution Approach 1:
The patent resolves this contradiction by endowing ZL-n-91 with local quality in the form of subtype-specific selectivity. The compound's molecular structure is tailored to recognize and bind specifically to PDE4D, allowing effective inhibition of tumor growth at lower doses without activating other PDE family members that would cause gastrointestinal side effects, thus breaking the dose-dependent side effect relationship
3Adaptability or versatility
If non-selective PDE4 inhibitors are used, then they can inhibit multiple PDE family members, but they lack specificity leading to limited clinical application
Solution Approach 1:
The patent applies local quality by confining the inhibitory action of ZL-n-91 to a specific target (PDE4D) rather than allowing broad PDE family inhibition. This selective targeting approach, achieved through the compound's specific molecular structure and binding characteristics, enhances clinical applicability by eliminating the side effect profile associated with non-selective PDE inhibition while maintaining effective anti-tumor activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ZL-n-91 effectively inhibits lung cancer cell proliferation and metastasis, potentially improving the prognosis for lung cancer patients with a higher selectivity for PDE4D, reducing adverse reactions, and prolonging survival time in animal models.
Implementation Method 1
Phosphodiesterases (PDEs) have the function of hydrolyzing intracellular second messenger cAMP or cGMP... PDE4 specifically hydrolyzes cAMP... PDE4 inhibitor ZL-n-91... has a high selectivity for PDE4D, significantly inhibiting lung cancer cell proliferation and metastasis
Data Source
AI summary
The present invention discloses uses of a novel phosphodiesterase 4 (PDE4) inhibitor ZL-n-91 in preparing drugs against lung cancer proliferation and metastasis. The mouse survival curves and in vitro cell experiments show that the PDE4 inhibitor ZL-n-91 can significantly inhibit the proliferation and metastasis of lung cancer cells, indicating that this PDE4 inhibitor ZL-n-91 can become an important target for the studies on anti-lung cancer proliferation and metastasis, to provide a basis for preparing drugs against lung cancer proliferation and metastasis, with promising prospect of development and application.